JP2013537174A5 - - Google Patents

Download PDF

Info

Publication number
JP2013537174A5
JP2013537174A5 JP2013527575A JP2013527575A JP2013537174A5 JP 2013537174 A5 JP2013537174 A5 JP 2013537174A5 JP 2013527575 A JP2013527575 A JP 2013527575A JP 2013527575 A JP2013527575 A JP 2013527575A JP 2013537174 A5 JP2013537174 A5 JP 2013537174A5
Authority
JP
Japan
Prior art keywords
amino
imidazo
cyclopropyl
methylbenzamide
pyridazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013527575A
Other languages
English (en)
Japanese (ja)
Other versions
JP5824050B2 (ja
JP2013537174A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/065368 external-priority patent/WO2012032031A1/en
Publication of JP2013537174A publication Critical patent/JP2013537174A/ja
Publication of JP2013537174A5 publication Critical patent/JP2013537174A5/ja
Application granted granted Critical
Publication of JP5824050B2 publication Critical patent/JP5824050B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013527575A 2010-09-10 2011-09-06 置換イミダゾピリダジン類 Expired - Fee Related JP5824050B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP10176134 2010-09-10
EP10176134.4 2010-09-10
EP11075022.1 2011-02-04
EP11075022 2011-02-04
EP11170771.7 2011-06-21
EP11170775.8 2011-06-21
EP11170775 2011-06-21
EP11170771 2011-06-21
PCT/EP2011/065368 WO2012032031A1 (en) 2010-09-10 2011-09-06 Substituted imidazopyridazines

Publications (3)

Publication Number Publication Date
JP2013537174A JP2013537174A (ja) 2013-09-30
JP2013537174A5 true JP2013537174A5 (enExample) 2014-10-09
JP5824050B2 JP5824050B2 (ja) 2015-11-25

Family

ID=44545741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013527575A Expired - Fee Related JP5824050B2 (ja) 2010-09-10 2011-09-06 置換イミダゾピリダジン類

Country Status (38)

Country Link
US (1) US9255100B2 (enExample)
EP (1) EP2614063B1 (enExample)
JP (1) JP5824050B2 (enExample)
KR (1) KR20140032337A (enExample)
CN (1) CN103370318B (enExample)
AP (1) AP3607A (enExample)
AR (1) AR082946A1 (enExample)
AU (1) AU2011298844B2 (enExample)
BR (1) BR112013005679A2 (enExample)
CA (1) CA2810755A1 (enExample)
CO (1) CO6720961A2 (enExample)
CR (1) CR20130102A (enExample)
CU (1) CU24187B1 (enExample)
CY (1) CY1117352T1 (enExample)
DK (1) DK2614063T3 (enExample)
DO (1) DOP2013000054A (enExample)
EA (1) EA023420B1 (enExample)
EC (1) ECSP13012752A (enExample)
ES (1) ES2568220T3 (enExample)
HR (1) HRP20160360T1 (enExample)
HU (1) HUE028771T2 (enExample)
IL (1) IL225058A (enExample)
MA (1) MA34516B1 (enExample)
ME (1) ME02389B (enExample)
MX (1) MX2013002713A (enExample)
MY (1) MY185139A (enExample)
NZ (1) NZ607904A (enExample)
PE (1) PE20131164A1 (enExample)
PH (1) PH12013500454A1 (enExample)
PL (1) PL2614063T3 (enExample)
RS (1) RS54661B1 (enExample)
SA (1) SA111320735B1 (enExample)
SG (1) SG188417A1 (enExample)
SI (1) SI2614063T1 (enExample)
TW (1) TWI541243B (enExample)
UY (1) UY33598A (enExample)
WO (1) WO2012032031A1 (enExample)
ZA (1) ZA201301756B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
PL3409278T3 (pl) 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy białkowej
JP6166289B2 (ja) * 2012-03-14 2017-07-19 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換イミダゾピリダジン
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
EP2920181B1 (en) 2012-11-16 2019-01-09 University Health Network Pyrazolopyrimidine compounds
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TW201437211A (zh) * 2013-03-01 2014-10-01 Bayer Pharma AG 經取代咪唑并嗒□
TWI649318B (zh) 2013-04-19 2019-02-01 英塞特控股公司 作為fgfr抑制劑之雙環雜環
PT3008062T (pt) 2013-06-11 2017-06-07 Bayer Pharma AG Derivados de profármaco de triazolopiridinas substituídas
HK1222341A1 (zh) * 2013-06-13 2017-06-30 Bayer Pharma Aktiengesellschaft 咪唑并哒嗪衍生物与有丝分裂试剂的联用药用於治疗癌症
CN103360399B (zh) * 2013-08-02 2016-03-02 北京大学 6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物,其制备方法及用途
GB201321734D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
WO2015127284A2 (en) * 2014-02-21 2015-08-27 Frost Biologic, Inc. Antimitotic amides for the treatment of cancer and proliferative disorders
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
TW201613927A (en) * 2014-09-01 2016-04-16 Bayer Pharma AG Method for preparation of substituted imidazopyridazines
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CN107567503B (zh) 2015-04-17 2022-03-22 荷兰转化研究中心有限责任公司 用于ttk抑制剂化疗的预后生物标记
WO2016187028A1 (en) * 2015-05-15 2016-11-24 Celgene Avilomics Research, Inc. Heteroaryl compounds, synthesis thereof, and intermediates thereto
CA3007214C (en) * 2015-12-04 2023-10-03 Exxonmobil Research And Engineering Company Emm-28, a novel synthetic crystalline material, its preparation and use
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
RU2753905C2 (ru) 2016-07-18 2021-08-24 Юниверсити Хелс Нетуорк Твердые формы ингибитора ttk
CN110753560B (zh) * 2017-04-11 2022-07-26 斯特劳曼控股公司 牙科植入物
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
ES2991427T3 (es) 2018-05-04 2024-12-03 Incyte Corp Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas
TW201946630A (zh) 2018-05-04 2019-12-16 美商英塞特公司 Fgfr抑制劑之鹽
PL3792260T3 (pl) 2018-05-08 2024-12-02 Nippon Shinyaku Co., Ltd. Związki azabenzimidazolowe i środki farmaceutyczne
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN111978325B (zh) * 2019-05-22 2023-11-17 中国药科大学 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GEAP202415945A (en) 2019-10-14 2024-04-25 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021095801A1 (ja) 2019-11-13 2021-05-20 日本新薬株式会社 アザベンゾイミダゾール化合物及び医薬
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
MX2024007450A (es) * 2021-12-15 2024-07-04 Sillajen Inc Combinaciones farmaceuticas para utilizarse en el tratamiento de enfermedades neoplasicas.
WO2024155837A1 (en) * 2023-01-19 2024-07-25 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2273369T3 (es) 1996-08-28 2007-05-01 Pfizer Inc. Derivados 6,5 heterobiciclicos sustituidos.
JP3729343B2 (ja) 2000-04-27 2005-12-21 アステラス製薬株式会社 縮合ヘテロアリール誘導体
AR045697A1 (es) 2003-07-14 2005-11-09 Arena Pharm Inc Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo
WO2005080355A1 (en) 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007058942A2 (en) * 2005-11-10 2007-05-24 Schering Corporation Imidazopyrazines as protein kinase inhibitors
TW200840584A (en) * 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
JP2010524953A (ja) * 2007-04-17 2010-07-22 ブリストル−マイヤーズ スクイブ カンパニー 縮合ヘテロ環11−β−ヒドロキシステロイドデヒドロゲナーゼI型阻害剤
WO2009060197A1 (en) 2007-11-08 2009-05-14 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazopyridazines for use as protein kinase inhibitors
WO2009100375A1 (en) 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CN102413831B (zh) 2009-04-29 2014-06-04 拜耳知识产权有限责任公司 取代的咪唑并喹喔啉
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
CA2772790C (en) 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
CN102971321B (zh) 2010-03-18 2015-07-29 拜耳知识产权有限责任公司 咪唑并吡嗪
ES2555261T3 (es) 2010-06-01 2015-12-30 Bayer Intellectual Property Gmbh Imidazopirazinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
JP5824065B2 (ja) 2010-12-17 2015-11-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 過剰増殖性障害の治療におけるmps−1およびtkk阻害剤として使用するための6置換イミダゾピラジン
EP2651947B1 (en) 2010-12-17 2014-12-10 Bayer Intellectual Property GmbH 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CN103370322B (zh) 2010-12-17 2016-02-10 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪
CN103429592A (zh) 2010-12-17 2013-12-04 拜耳知识产权有限责任公司 作为mps-1和tkk抑制剂用于治疗过度增殖性病症的6-取代的咪唑并吡嗪
EP2651948A1 (en) 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
EP2651950A1 (en) 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders

Similar Documents

Publication Publication Date Title
JP2013537174A5 (enExample)
JP6473457B2 (ja) Shp2の活性を阻害するための1−(トリアジン−3−イル/ピリダジン−3−イル)−ピペリジン/ピペラジン誘導体およびその組成物
US10975080B2 (en) Compounds and compositions for inhibiting the activity of SHP2
US20220241261A1 (en) Combinations of inhibitors of irak4 with inhibitors of btk
CN109415360B (zh) 用于抑制shp2活性的化合物和组合物
US9926314B2 (en) Compounds and compositions for the treatment of parasitic diseases
US9555031B2 (en) Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity
HRP20160360T1 (hr) Supstituirani imidazopiridazini
KR102891807B1 (ko) 치료 헤테로시클릭 화합물
JP2016505529A5 (enExample)
US20150291598A1 (en) Compounds and compositions for the treatment of parasitic diseases
ES2946060T3 (es) Compuestos y composiciones de urea como inhibidores de SMARCA2/BRM-ATPASA
US10689378B2 (en) Triazolopyridine compounds and uses thereof
JP2018517746A (ja) Shp2の活性を阻害するための化合物および組成物
JP2017502993A (ja) Shp2の活性を阻害するためのn−アザスピロシクロアルカン置換n−ヘテロアリール化合物および組成物
JP2016522232A5 (enExample)
TW200908969A (en) Organic compounds
EA019064B1 (ru) Способы лечения рака с применением хинаксолинового ингибитора pi3k-альфа
JP2019507122A (ja) クリプトスポリジウム症の治療のための化合物および組成物
RU2021107655A (ru) Соединения триазоло-пиримидина и их применение